Storia in 2 fonti

Why Is Turn Therapeutics Stock Trading Higher Today? - Turn Therapeutics (NASDAQ:TTRX)

Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a broader atopic dermatitis population.

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo3 g fa

Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a broader atopic dermatitis population.

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis